newsfilter
← Latest News
Business Wire·

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, fo